Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

Stopped early · Phase 2

Conditions studied: Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer

In brief

ADU-CL-20 is an open-label, multicenter Phase 2 clinical trial to evaluate the efficacy and safety of intratumoral ADU-S100 (also referred to as MIW815) administered with pembrolizumab in the first-line setting. The population will consist of adults with PD-L1 positive recurrent or metastatic HNSCC.

Key facts

Study ID
NCT03937141
Run by
Chinook Therapeutics, Inc. (formerly Aduro)
People needed
16
Starts
2019-08-26
Expected to finish
2021-06-10
Last updated by the study team
2022-01-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.